Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sanofi SA (SNY) vs Simon Property Group Inc (SPG) Price & Performance

Sanofi SATrade
Simon Property Group IncTrade

Price performance (Past 24H)

Key statistics

Sanofi SA vs Simon Property Group Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Simon Property Group Inc trades at $227 (market cap $74.00B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.

SNYSPG
Market Cap
$104.83B$74.00B
Sector
HealthReal Estate
52-Week High
$52.34$228.70
52-Week Low
$41.33$160.68
Enterprise Value
$121.32B$102.48B
Dividend Yield
5.5%3.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.

Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.

Simon Property Group Inc

SPG trades at $226.79, down 0.84% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 earnings beating expectations at $1.48 per share versus $1.46 expected, continuing a pattern of earnings outperformance. Revenue growth has accelerated from $5.3B in 2022 to $6.4B in 2025, while net income surged to $4.63B with a remarkable 72.7% profit margin. Recent corporate developments include a $2.25 dividend payment and Euro-denominated note offering.

SPG presents a compelling investment case with strong operational performance and dividend yield exceeding 4%, though current valuation metrics suggest limited upside from analyst consensus targets. Key risks include high leverage with $24.21B long-term debt and sensitivity to interest rate movements. The stock's technical overbought condition near resistance levels warrants caution despite positive earnings momentum and institutional support.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY

About Simon Property Group Inc

Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.

Read more on SPG